97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05118919 (ClinicalTrials.gov) | February 9, 2022 | 26/10/2021 | A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis | A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis | Ulcerative Colitis | Biological: BGP-014;Biological: Placebo | BioGaia Pharma AB | NULL | Recruiting | 18 Years | N/A | All | 50 | Phase 1/Phase 2 | Sweden |
| 2 | EUCTR2019-004578-25-SE (EUCTR) | 09/07/2021 | 27/12/2019 | A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014 | A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis | Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: BGP-014 Capsules Product Code: BGP-014 INN or Proposed INN: Lactobacillus reuteri Other descriptive name: LACTOBACILLUS REUTERI | BioGaia Pharma AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 1;Phase 2 | Sweden |